Study on the Safety and Effectiveness of TNG462 Combination Therapy in Pancreatic and Lung Cancer Patients

Inclusion Criteria

• Must be 18 years or older.
• Have a performance status score of 0 or 1, indicating full activity or some restriction in strenuous activities.
• Have a tumor with a specific genetic change called MTAP loss or RAS mutation.
• Have advanced pancreatic cancer or lung cancer that has spread or cannot be removed by surgery.
• Have received previous standard treatments for their cancer.
• Must not have received previous treatments targeting RAS mutations.
• Have measurable cancer that can be tracked using standard criteria.
• Have good organ function as determined by specific tests.
• Must be able to swallow tablets.
• Women must have a negative pregnancy test before starting the study.
• Must provide written informed consent to participate.

Exclusion Criteria

• Have received previous treatments with specific inhibitors related to the study drugs.
• Have participated in previous trials of RMC-6236 or RMC-9805.
• Have allergies or intolerances to the study drugs or their ingredients.
• Have uncontrolled illnesses that would interfere with the study.
• Have active infections requiring treatment.
• Are participating in another clinical trial or plan to do so.
• Have digestive issues that affect medication absorption.
• Have untreated or worsening brain metastases.
• Have active liver disease.
• Are HIV positive unless specific health criteria are met.
• Have significant heart disease.
• Have lung diseases like interstitial lung disease.
• Are pregnant or breastfeeding.
• Are unable or unwilling to follow the study schedule and procedures.
• Have other significant health issues that could affect safety or study results.